A Quiet but Productive Week: New Biology, a Natural Compound in the Spotlight, and Fresh Computer Hypotheses

Where things stand now

IPF still has no cure, and that has not changed. The two approved drugs that slow scarring are pirfenidone and nintedanib (older standards), plus nerandomilast (brand name Jascayd), which the FDA approved in October 2025. These medicines can slow the disease down but cannot undo the scar tissue already in the lungs. Inhaled treprostinil is in late-stage trials with an FDA filing expected in 2026, and admilparant is in a Phase III trial called ALOFT-IPF. Both are investigational and not yet approved. Rentosertib is in earlier human trials and is also investigational. Research into actually regenerating lung tissue remains in the preclinical stage, meaning it has not yet been tested in people.

The best option right now

For someone with IPF right now, the honest answer is that approved medicines can slow the disease but nothing available today reverses or cures it. Nerandomilast (Jascayd) is the newest FDA-approved option, joining the older approved drugs. Inhaled treprostinil and admilparant look promising in trials but are not approved yet. Every patient's situation is different, so the right choice depends on a conversation with a specialist who knows your case. No drug on this list is guaranteed to work for any individual.

How close are we to regeneration

Regenerating scarred lung tissue is a research goal, not an available treatment. The most advanced experimental approaches in the data are uPAR-CAR-T cells, which are engineered immune cells designed to clear out old, stuck cells called senescent cells, tested only in animals so far. A combined approach using senolytics (drugs that clear senescent cells) plus a molecule called RSPO3 to encourage lung stem cells to regrow is still at the concept and animal-testing stage. Both are preclinical, meaning no human trials have started. Realistic timeline estimates are not possible from the current data.

Study of the week

This week's most notable paper, chosen by the PF-Atlas editorial team, comes from Wang, Yin, and Niu, published in Chinese Journal of Natural Medicines in 2026. The researchers looked at a natural compound called syringin, found in plants like Siberian ginseng. They tested it in lab models of IPF and found it appeared to interact with a biological pathway called the ATR/CHK1-p53 axis. This pathway is connected to cellular aging and stress responses that contribute to lung scarring. The results are early and come from lab models, not from humans, so syringin is an experimental compound and not a treatment. It is interesting because it points researchers toward a new biological target, but many steps of further testing would be needed before anyone could know whether it helps people with IPF.

What changed since last week

No trials opened or changed status this week. The pool of approved and investigational treatments is the same as last week. Twelve new papers arrived, adding detail to several biological mechanisms but not changing the overall picture of what is available to patients.

What our own software did this week

This section describes output from PF-Atlas's own software, a genetic-algorithm solver combined with an AI literature scanner. This is our own computer model, not outside research, and its outputs are computer-generated hypotheses only. They are not treatments, not clinical evidence, and have not been tested in people. This week our software proposed four new drug candidates worth investigating: inhaled triiodothyronine (a thyroid hormone) delivered in a liposomal nanoparticle, an anti-DLL4 monoclonal antibody similar to demcizumab given at low dose, an inhaled siRNA molecule targeting a gene called SPDEF, and an inhaled bispecific molecule designed to activate SLIT2 and ROBO1 signaling to encourage lung cell repair. The software also added three compounds to its working pool for future analysis: chlorogenic acid (a plant-derived molecule), an AEC2-targeted mRNA therapeutic concept, and a Piezo1 mechanosensing inhibitor from a compound class called GsMTx4. All of these are computer-generated starting points for scientists to evaluate, nothing more.

Sources this week

• Research on the role and mechanism of SLC7A5 in idiopathic pulmonary fibrosis. · Molecular medicine reports 2026 PMID 42825353 on PubMed ↗
• Pleuroparenchymal fibroelastosis in a UK tertiary ILD centre: determinants of radiological progression and survival. · Respiratory medicine 2026 PMID 42829080 on PubMed ↗
• Management of Pulmonary Hypertension in Interstitial Lung Disease Without Access to Inhaled Treprostinil: A Case Series from a Resource-Limited Setting. · The American journal of the medical sciences 2026 PMID 42826861 on PubMed ↗
• Platelet GPVI drives fibrotic lung remodeling. · Blood advances 2026 PMID 42826704 on PubMed ↗
• The Ethics of Lung Cancer Education for Pulmonary Fibrosis Patients: Addressing Diagnostic Overshadowing and Cancer Risk. · Journal of cancer education : the official journal of the American Association for Cancer Education 2026 PMID 42825871 on PubMed ↗
• End of rarity: the evolving burden of interstitial lung diseases in England - trends from a national population-based cohort study. · Thorax 2026 PMID 42823350 on PubMed ↗
• Evaluation of Pirfenidone as a Novel Radioprotectant for Radiation-induced Intestinal Injury. · Anticancer research 2026 PMID 42823179 on PubMed ↗
• Multi-omics integration reveals the CTSK-cholesterol metabolic axis and the cholesterol-RORA/LDLR paracrine axis in SPP1(+) macrophages as mediators of 6PPD-quinone-induced idiopathic pulmonary fibrosis. · Environmental pollution (Barking, Essex : 1987) 2026 PMID 42822817 on PubMed ↗
• Advances in Prognostic Assessment of Idiopathic Pulmonary Fibrosis: From Clinical-Physiological Parameters and Molecular Biomarkers to Multimodal Models. · Respiratory medicine 2026 PMID 42822813 on PubMed ↗
• Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis. · Chinese journal of natural medicines 2026 PMID 42816034 on PubMed ↗
• Cadherin-11 regulation of type II alveolar epithelial cells during pulmonary fibrosis. · American journal of physiology. Cell physiology 2026 PMID 42750185 on PubMed ↗
• Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report. · JTO clinical and research reports 2026 PMID 42733924 on PubMed ↗
• Evaluation of radiological lung pattern and disease progression in patients with asbestosis compared to patients with idiopathic pulmonary fibrosis. · Respiratory medicine 2026 PMID 42660370 on PubMed ↗
• Deciphering the pulmonary fibrosis niche: A single-cell transcriptomic perspective on cellular crosstalk and microenvironment remodeling. · Cytokine & growth factor reviews 2026 PMID 42636652 on PubMed ↗
• Prognostic impact of autoimmune features in interstitial lung disease: a single-center retrospective real-world cohort study. · Clinical rheumatology 2026 PMID 42631904 on PubMed ↗
• Aberrant expression of the PREX2-MAGI2 axis modulates myofibroblast differentiation in pulmonary fibrosis. · American journal of physiology. Lung cellular and molecular physiology 2026 PMID 42631393 on PubMed ↗
• Occupational disease risks in natural resource-based industries among a large cohort of workers in Ontario, Canada. · Work (Reading, Mass.) 2026 PMID 42627631 on PubMed ↗
• MicroRNAs in IPF and lung cancer: convergent and divergent mechanisms: a systematic review. · American journal of physiology. Lung cellular and molecular physiology 2026 PMID 42586526 on PubMed ↗
• GSNOR reprograms nitrosylation to drive endothelial-to-mesenchymal transition and fibrotic vascular remodeling. · Redox biology 2026 PMID 42579926 on PubMed ↗
• Comparative study on mouse models of acute exacerbation of pulmonary fibrosis. · Experimental and therapeutic medicine 2026 PMID 42577630 on PubMed ↗